Immunicum
Immunicum: Promising GIST trial results (Redeye)
2019-06-13 15:00
The GIST trial top-line results confirm an excellent safety and tolerability profile of ilixadencel. Somewhat surprisingly, two out of a total of six patients included in the trial showed partial response to treatment. We reiterate our base case fair value of SEK 16.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se